Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2019-03-21 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-03-21 English
Regulatory Filings 2019
Regulatory Filings
2019-03-21 English
424B3
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a proxy statement/prospectus related to a merger proposal between OncoMed Pharmaceuticals, Inc. and Mereo BioPharma Group plc. It includes detailed information about the merger agreement, voting instructions for stockholders, meeting details, and recommendations from the board of directors. The document is filed pursuant to Rule 424(b)(3), which is a prospectus filing related to securities offerings in connection with mergers. The content focuses on soliciting shareholder votes for the merger and related proposals, typical of proxy solicitation materials. It is not a full merger agreement filing (like a DEFM14A), nor is it a simple announcement or voting results. Given the detailed solicitation and proxy information, the document fits best under Proxy Solicitation & Information Statement (PSI).
2019-03-20 English
Regulatory Filings 2019
Regulatory Filings
2019-03-19 English
F-4/A
Merger & Acquisition Classification · 100% confidence The document is a Form F-4/A Registration Statement filed with the SEC, which is used for registering securities in connection with merger transactions. It includes detailed information about a merger proposal between Mereo BioPharma Group plc and OncoMed Pharmaceuticals, Inc., including the merger agreement, proxy statement/prospectus, voting instructions, and related disclosures. The document is not a simple announcement but a comprehensive filing related to a merger transaction, including solicitation of shareholder votes and detailed merger terms. This fits the definition of a Merger & Acquisition filing (MA), which covers merger, acquisition, and tender-offer filings such as Form F-4. The document length (15,000 characters) and content confirm it is the filing itself, not just an announcement or proxy solicitation material alone.
2019-03-15 English
Update on Proposed Combination of Mereo & OncoMed
M&A Activity Classification · 100% confidence The document is an official announcement regarding the progress of a proposed merger (combination) between Mereo BioPharma and OncoMed Pharmaceuticals. It details the receipt of support agreements from shareholders and provides updates on the transaction timeline and related corporate actions (such as a special dividend). This falls squarely under the definition of M&A activity (merger proposals or takeover bids).
2019-03-15 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.